Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

British Journal of Clinical Pharmacology

Volumn 73, Issue 4, 2012, Pages 579-587

  Shoaf, Susan E ^a   Bricmont, Patricia ^a   Mallikaarjun, Suresh ^a  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

CYP3A induction; CYP3A inhibition; Pharmacodynamics; Pharmacokinetics; Tolvaptan

Indexed keywords

CYTOCHROME P450 3A4; ERYTHROMYCIN; KETOCONAZOLE; PLACEBO; RIFAMPICIN; TOLVAPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINARY EXCRETION; URINE VOLUME;

14-ALPHA DEMETHYLASE INHIBITORS; ADOLESCENT; ADULT; AREA UNDER CURVE; BENZAZEPINES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; RIFAMPIN; URINATION; YOUNG ADULT;

EID: 84858202663     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.04114.x     Document Type: Article

References (21)

1. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998; 287: 860-7.
2. King LS, Agre P. Pathophysiology of the aquaporin water channels. Annu Rev Physiol 1996; 58: 619-48.
3. Shoaf SE, Wang Z, Bricmont P, Mallikaarjun S. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007; 47: 1498-507.
4. Hauptman PJ, Zimmer C, Udelson J, Shoaf SE, Mallikaarjun S, Bramer SL, Orlandi C. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure. J Cardiovasc Pharmacol 2005; 46: 609-14.
5. Shoaf SE, Ohzone Y, Ninomiya SI, Furukawa M, Bricmont P, Kashiyama E, Mallikaarjun S. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects. J Clin Pharmacol 2010; 51: 761-9.
6. Samsca® (Tolvaptan): EU Summary of Product Characteristics. Uxbridge: Otsuka Pharmaceutical Europe Ltd, 2009.
7. Tolvaptan (Samsca) for hyponatremia. Med Lett Drugs Ther 2009; 51: 95-6.
8. Thompson CA. FDA approves oral vasopressin antagonist. Am J Health Syst Pharm 2009; 66: 1154.
9. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am 1997; 81: 585-609.
10. Stoch SA, Friedman E, Maes A, Yee K, Xu Y, Larson P, Fitzgerald M, Chodakewitz J, Wagner JA. Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. Clin Pharmacol 2009; 49: 398-406.
11. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
12. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, eds Evans WE, Jusko WJ, Schentag JJ. Vancouver, WA: Lippincott Williams & Wilkins, 1992; 1202.
13. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999; 66: 461-71.
14. Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJJ, Wilkinson GE. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999; 66: 224-31.
15. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994; 56: 608-14.
16. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989; 83: 688-97.
17. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole. Am J Clin Oncol 1997; 20: 592-9.
18. McCrea J, Prueksaritanont T, Gertz BJ, Carides A, Gillen L, Antonello S, Brucker MJ, Miller-Stein C, Osborne B, Waldman S. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol 1999; 39: 1212-20.
19. Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 2007; 50: 213-22.
20. Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 2005; 97: 249-56.
21. Rifadin (rifampin) [Package Insert]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, revised July 2008. Available at (last accessed 27 October 2011).